{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:42:54Z","timestamp":1785782574370,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,26]]},"DOI":"10.7759\/cureus.83022","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T08:02:32Z","timestamp":1745654552000},"source":"Crossref","is-referenced-by-count":7,"title":["Molecular Mechanisms and Emerging Precision Therapeutics in the Gut Microbiota-Cardiovascular Axis"],"prefix":"10.7759","author":[{"given":"Jhon Alexander","family":"Ponce Alencastro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Alejandro","family":"Salinas Lucero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Perez","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota Griselda","family":"Herrera Giron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s Sebasti\u00e1n","family":"Estrella L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Xavier","family":"Anda Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03217-2","article-title":"Diabetes, hypertension, and cardiovascular disease development","volume":"20","author":"Yen FS","year":"2022","unstructured":"Yen FS, Wei JC, Chiu LT, Hsu CC, Hwu CM. Diabetes, hypertension, and cardiovascular disease development. J Transl Med. 2022, 20:9. 10.1186\/s12967-021-03217-2","journal-title":"J Transl Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwac285","article-title":"Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990-2019: findings from 2019 global burden of disease study","volume":"30","author":"Li Y","year":"2023","unstructured":"Li Y, Cao GY, Jing WZ, Liu J, Liu M. Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990-2019: findings from 2019 global burden of disease study. Eur J Prev Cardiol. 2023, 30:276-86. 10.1093\/eurjpc\/zwac285","journal-title":"Eur J Prev Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.817808","article-title":"Unhealthy dietary habits and obesity: the major risk factors beyond non-communicable diseases in the eastern mediterranean region","volume":"9","author":"Al-Jawaldeh A","year":"2022","unstructured":"Al-Jawaldeh A, Abbass MM. Unhealthy dietary habits and obesity: the major risk factors beyond non-communicable diseases in the eastern mediterranean region. Front Nutr. 2022, 9:817808. 10.3389\/fnut.2022.817808","journal-title":"Front Nutr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.903570","article-title":"The gut microbiota (microbiome) in cardiovascular disease and its therapeutic regulation","volume":"12","author":"Rahman MM","year":"2022","unstructured":"Rahman MM, Islam F, Or-Rashid MH, et al.. The gut microbiota (microbiome) in cardiovascular disease and its therapeutic regulation. Front Cell Infect Microbiol. 2022, 12:903570. 10.3389\/fcimb.2022.903570","journal-title":"Front Cell Infect Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan Y","year":"2021","unstructured":"Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021, 19:55-71. 10.1038\/s41579-020-0433-9","journal-title":"Nat Rev Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010144","article-title":"Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review","volume":"13","author":"Duttaroy AK","year":"2021","unstructured":"Duttaroy AK. Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review. Nutrients. 2021, 13:144. 10.3390\/nu13010144","journal-title":"Nutrients"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910634","article-title":"Cardiovascular disease may be triggered by gut microbiota, microbial metabolites, gut wall reactions, and inflammation","volume":"25","author":"Dicks LM","year":"2024","unstructured":"Dicks LM. Cardiovascular disease may be triggered by gut microbiota, microbial metabolites, gut wall reactions, and inflammation. Int J Mol Sci. 2024, 25:10634. 10.3390\/ijms251910634","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.4391","article-title":"Interventions to mitigate risk of cardiovascular disease after adverse pregnancy outcomes: a review","volume":"7","author":"Jowell AR","year":"2021","unstructured":"Jowell AR, Sarma AA, Gulati M, et al.. Interventions to mitigate risk of cardiovascular disease after adverse pregnancy outcomes: a review. JAMA Cardiol. 2021, 7:346-55. 10.1001\/jamacardio.2021.4391","journal-title":"JAMA Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00974-4","article-title":"Microbiota in health and diseases","volume":"7","author":"Hou K","year":"2022","unstructured":"Hou K, Wu ZX, Chen XY, et al.. Microbiota in health and diseases. Signal Transduct Target Ther. 2022, 7:135. 10.1038\/s41392-022-00974-4","journal-title":"Signal Transduct Target Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051799","article-title":"Precision medicine and the future of cardiovascular diseases: a clinically oriented comprehensive review","volume":"12","author":"Sethi Y","year":"2023","unstructured":"Sethi Y, Patel N, Kaka N, et al.. Precision medicine and the future of cardiovascular diseases: a clinically oriented comprehensive review. J Clin Med. 2023, 12:1799. 10.3390\/jcm12051799","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/gidisord7010007","article-title":"Microbiome-driven therapeutics: from gut health to precision medicine","volume":"7","author":"Yaqub MO","year":"2025","unstructured":"Yaqub MO, Jain A, Joseph CE, Edison LK. Microbiome-driven therapeutics: from gut health to precision medicine. Gastrointest Disord. 2025, 7:7. 10.3390\/gidisord7010007","journal-title":"Gastrointest Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1535370219900898","article-title":"Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system","volume":"245","author":"Onyszkiewicz M","year":"2020","unstructured":"Onyszkiewicz M, Jaworska K, Ufnal M. Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system. Exp Biol Med (Maywood). 2020, 245:166-75. 10.1177\/1535370219900898","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.17583","article-title":"Microbiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: a prospective, open label, controlled, randomized, comparative, proof of concept study","volume":"12","author":"Kallapura G","year":"2024","unstructured":"Kallapura G, Prakash AS, Sankaran K, Manjappa P, Chaudhary P, Ambhore S, Dhar D. Microbiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: a prospective, open label, controlled, randomized, comparative, proof of concept study. PeerJ. 2024, 12:e17583. 10.7717\/peerj.17583","journal-title":"PeerJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000720","article-title":"Gut microbiome and cardiovascular disease","volume":"35","author":"Zhao Y","year":"2020","unstructured":"Zhao Y, Wang Z. Gut microbiome and cardiovascular disease. Curr Opin Cardiol. 2020, 35:207-18. 10.1097\/HCO.0000000000000720","journal-title":"Curr Opin Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00900-1","article-title":"The gut microbiome in atherosclerotic cardiovascular disease","volume":"8","author":"Jie Z","year":"2017","unstructured":"Jie Z, Xia H, Zhong SL, et al.. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017, 8:845. 10.1038\/s41467-017-00900-1","journal-title":"Nat Commun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.169","article-title":"Atherosclerosis: association between the gut microbiome and atherosclerosis","volume":"14","author":"Barrington WT","year":"2017","unstructured":"Barrington WT, Lusis AJ. Atherosclerosis: association between the gut microbiome and atherosclerosis. Nat Rev Cardiol. 2017, 14:699-700. 10.1038\/nrcardio.2017.169","journal-title":"Nat Rev Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.14800","article-title":"Modest sodium reduction increases circulating short-chain fatty acids in untreated hypertensives: a randomized, double-blind, placebo-controlled trial","volume":"76","author":"Chen L","year":"2020","unstructured":"Chen L, He FJ, Dong Y, Huang Y, Wang C, Harshfield GA, Zhu H. Modest sodium reduction increases circulating short-chain fatty acids in untreated hypertensives: a randomized, double-blind, placebo-controlled trial. Hypertension. 2020, 76:73-9. 10.1161\/HYPERTENSIONAHA.120.14800","journal-title":"Hypertension"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1936379","article-title":"Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases","volume":"13","author":"Xu J","year":"2021","unstructured":"Xu J, Yang Y. Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases. Gut Microbes. 2021, 13:1936379. 10.1080\/19490976.2021.1936379","journal-title":"Gut Microbes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.01.007","article-title":"Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis","volume":"31","author":"Tian R","year":"2021","unstructured":"Tian R, Liu H, Feng S, et al.. Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis. Nutr Metab Cardiovasc Dis. 2021, 31:1454-66. 10.1016\/j.numecd.2021.01.007","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034230","article-title":"Disordered gut microbiome and alterations in metabolic patterns are associated with hypertensive left ventricular hypertrophy","volume":"13","author":"Cao R","year":"2024","unstructured":"Cao R, Gao T, Yue J, Sun G, Yang X. Disordered gut microbiome and alterations in metabolic patterns are associated with hypertensive left ventricular hypertrophy. J Am Heart Assoc. 2024, 13:e034230. 10.1161\/JAHA.123.034230","journal-title":"J Am Heart Assoc"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010054","article-title":"The role of gut dysbiosis in the pathophysiology of neuropsychiatric disorders","volume":"12","author":"Anand N","year":"2022","unstructured":"Anand N, Gorantla VR, Chidambaram SB. The role of gut dysbiosis in the pathophysiology of neuropsychiatric disorders. Cells. 2022, 12:54. 10.3390\/cells12010054","journal-title":"Cells"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00987-1","article-title":"Complex regulatory\u00a0effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity","volume":"20","author":"Kim CH","year":"2023","unstructured":"Kim CH. Complex regulatory\u00a0effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity. Cell Mol Immunol. 2023, 20:341-50. 10.1038\/s41423-023-00987-1","journal-title":"Cell Mol Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaa022","article-title":"Genomic determinants of hypertension with a focus on metabolomics and the gut microbiome","volume":"33","author":"Louca P","year":"2020","unstructured":"Louca P, Menni C, Padmanabhan S. Genomic determinants of hypertension with a focus on metabolomics and the gut microbiome. Am J Hypertens. 2020, 33:473-81. 10.1093\/ajh\/hpaa022","journal-title":"Am J Hypertens"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab309","article-title":"The gut microbiome in subclinical atherosclerosis: a population-based multiphenotype analysis","volume":"61","author":"Zhu S","year":"2021","unstructured":"Zhu S, Xu K, Jiang Y, et al.. The gut microbiome in subclinical atherosclerosis: a population-based multiphenotype analysis. Rheumatology (Oxford). 2021, 61:258-69. 10.1093\/rheumatology\/keab309","journal-title":"Rheumatology (Oxford)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.315890","article-title":"The molecular basis of predicting atherosclerotic cardiovascular disease risk","volume":"128","author":"Nayor M","year":"2021","unstructured":"Nayor M, Brown KJ, Vasan RS. The molecular basis of predicting atherosclerotic cardiovascular disease risk. Circ Res. 2021, 128:287-303. 10.1161\/CIRCRESAHA.120.315890","journal-title":"Circ Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-019-09519-7","article-title":"The gut microbiome and heart failure: a better gut for a better heart","volume":"20","author":"Branchereau M","year":"2019","unstructured":"Branchereau M, Burcelin R, Heymes C. The gut microbiome and heart failure: a better gut for a better heart. Rev Endocr Metab Disord. 2019, 20:407-14. 10.1007\/s11154-019-09519-7","journal-title":"Rev Endocr Metab Disord"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7150\/thno.55946","article-title":"Multi-omics study reveals that statin therapy is associated with restoration of gut microbiota homeostasis and improvement in outcomes in patients with acute coronary syndrome","volume":"11","author":"Hu X","year":"2021","unstructured":"Hu X, Li H, Zhao X, et al.. Multi-omics study reveals that statin therapy is associated with restoration of gut microbiota homeostasis and improvement in outcomes in patients with acute coronary syndrome. Theranostics. 2021, 11:5778-93. 10.7150\/thno.55946","journal-title":"Theranostics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.03.014","article-title":"Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria","volume":"187","author":"Li C","year":"2024","unstructured":"Li C, Stra\u017ear M, Mohamed AM, et al.. Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria. Cell. 2024, 187:1834-52.e19. 10.1016\/j.cell.2024.03.014","journal-title":"Cell"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.17185","article-title":"Atherosclerosis, gut microbiome, and exercise in a meta-omics perspective: a literature review","volume":"12","author":"Tang H","year":"2024","unstructured":"Tang H, Huang Y, Yuan D, Liu J. Atherosclerosis, gut microbiome, and exercise in a meta-omics perspective: a literature review. PeerJ. 2024, 12:e17185. 10.7717\/peerj.17185","journal-title":"PeerJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329969","article-title":"Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases","volume":"73","author":"Vich Vila A","year":"2024","unstructured":"Vich Vila A, Zhang J, Liu M, Faber KN, Weersma RK. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases. Gut. 2024, 73:1909-20. 10.1136\/gutjnl-2023-329969","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.805812","article-title":"Alterations of gut microbiome and serum metabolome in coronary artery disease patients complicated with non-alcoholic fatty liver disease are associated with adverse cardiovascular outcomes","volume":"8","author":"Hu X","year":"2021","unstructured":"Hu X, Zhou R, Li H, Zhao X, Sun Y, Fan Y, Zhang S. Alterations of gut microbiome and serum metabolome in coronary artery disease patients complicated with non-alcoholic fatty liver disease are associated with adverse cardiovascular outcomes. Front Cardiovasc Med. 2021, 8:805812. 10.3389\/fcvm.2021.805812","journal-title":"Front Cardiovasc Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2023.0048","article-title":"The gut-heart axis: updated review for the roles of microbiome in cardiovascular health","volume":"53","author":"Bui TV","year":"2023","unstructured":"Bui TV, Hwangbo H, Lai Y, Hong SB, Choi YJ, Park HJ, Ban K. The gut-heart axis: updated review for the roles of microbiome in cardiovascular health. Korean Circ J. 2023, 53:499-518. 10.4070\/kcj.2023.0048","journal-title":"Korean Circ J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085041","article-title":"The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases","volume":"14","author":"Zhen J","year":"2023","unstructured":"Zhen J, Zhou Z, He M, et al.. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne). 2023, 14:1085041. 10.3389\/fendo.2023.1085041","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312511","article-title":"Microbiome-derived trimethylamine N-oxide (TMAO) as a multifaceted biomarker in cardiovascular disease: challenges and opportunities","volume":"25","author":"Jaworska K","year":"2024","unstructured":"Jaworska K, Kopacz W, Koper M, Ufnal M. Microbiome-derived trimethylamine N-oxide (TMAO) as a multifaceted biomarker in cardiovascular disease: challenges and opportunities. Int J Mol Sci. 2024, 25:12511. 10.3390\/ijms252312511","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221090503","article-title":"TMAO as a novel predictor of major adverse vascular events and recurrence in patients with large artery atherosclerotic ischemic stroke","volume":"28","author":"Chen YY","year":"2022","unstructured":"Chen YY, Ye ZS, Xia NG, Xu Y. TMAO as a novel predictor of major adverse vascular events and recurrence in patients with large artery atherosclerotic ischemic stroke. Clin Appl Thromb Hemost. 2022, 28:10760296221090503. 10.1177\/10760296221090503","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/nu15092211","article-title":"Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota","volume":"15","author":"Fusco W","year":"2023","unstructured":"Fusco W, Lorenzo MB, Cintoni M, et al.. Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota. Nutrients. 2023, 15:2211. 10.3390\/nu15092211","journal-title":"Nutrients"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/nu14245361","article-title":"Short chain fatty acid metabolism in relation to gut microbiota and genetic variability","volume":"14","author":"Ramos Meyers G","year":"2022","unstructured":"Ramos Meyers G, Samouda H, Bohn T. Short chain fatty acid metabolism in relation to gut microbiota and genetic variability. Nutrients. 2022, 14:5361. 10.3390\/nu14245361","journal-title":"Nutrients"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-024-13384-z","article-title":"Integration of metabolomics and other omics: from microbes to microbiome","volume":"108","author":"Go D","year":"2024","unstructured":"Go D, Yeon GH, Park SJ, et al.. Integration of metabolomics and other omics: from microbes to microbiome. Appl Microbiol Biotechnol. 2024, 108:538. 10.1007\/s00253-024-13384-z","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/1177932219899051","article-title":"Multi-omics data integration, interpretation, and its application","volume":"14","author":"Subramanian I","year":"2020","unstructured":"Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights. 2020, 14:1177932219899051. 10.1177\/1177932219899051","journal-title":"Bioinform Biol Insights"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/art.42331","article-title":"Alterations of gut microbiome, metabolome, and lipidome in Takayasu arteritis","volume":"75","author":"Fan L","year":"2023","unstructured":"Fan L, Chen J, Pan L, et al.. Alterations of gut microbiome, metabolome, and lipidome in Takayasu arteritis. Arthritis Rheumatol. 2023, 75:266-78. 10.1002\/art.42331","journal-title":"Arthritis Rheumatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02467-22","article-title":"The microbial and metabolic signatures of patients with stable coronary artery disease","volume":"10","author":"Zhong J","year":"2022","unstructured":"Zhong J, Wu D, Zeng Y, et al.. The microbial and metabolic signatures of patients with stable coronary artery disease. Microbiol Spectr. 2022, 10:e0246722. 10.1128\/spectrum.02467-22","journal-title":"Microbiol Spectr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.imj.2022.08.004","article-title":"Correlation between human gut microbiome and diseases","volume":"1","author":"Madhogaria B","year":"2022","unstructured":"Madhogaria B, Bhowmik P, Kundu A. Correlation between human gut microbiome and diseases. Infect Med (Beijing). 2022, 1:180-91. 10.1016\/j.imj.2022.08.004","journal-title":"Infect Med (Beijing)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102649","article-title":"The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions","volume":"52","author":"Tr\u00f8seid M","year":"2020","unstructured":"Tr\u00f8seid M, Andersen G\u00d8, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions. EBioMedicine. 2020, 52:102649. 10.1016\/j.ebiom.2020.102649","journal-title":"EBioMedicine"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02260-4","article-title":"Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective","volume":"29","author":"Valles-Colomer M","year":"2023","unstructured":"Valles-Colomer M, Menni C, Berry SE, Valdes AM, Spector TD, Segata N. Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective. Nat Med. 2023, 29:551-61. 10.1038\/s41591-023-02260-4","journal-title":"Nat Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12030430","article-title":"Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives","volume":"12","author":"Abouelela ME","year":"2024","unstructured":"Abouelela ME, Helmy YA. Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives. Microorganisms. 2024, 12:430. 10.3390\/microorganisms12030430","journal-title":"Microorganisms"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-024-09398-5","article-title":"Next-generation probiotics: the upcoming biotherapeutics","volume":"51","author":"Al-Fakhrany OM","year":"2024","unstructured":"Al-Fakhrany OM, Elekhnawy E. Next-generation probiotics: the upcoming biotherapeutics. Mol Biol Rep. 2024, 51:505. 10.1007\/s11033-024-09398-5","journal-title":"Mol Biol Rep"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1511149","article-title":"Advancing microbiota therapeutics: the role of synthetic biology in engineering microbial communities for precision medicine","volume":"12","author":"Nazir A","year":"2024","unstructured":"Nazir A, Hussain FH, Raza A. Advancing microbiota therapeutics: the role of synthetic biology in engineering microbial communities for precision medicine. Front Bioeng Biotechnol. 2024, 12:1511149. 10.3389\/fbioe.2024.1511149","journal-title":"Front Bioeng Biotechnol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2024.107088","article-title":"Phage therapy: a targeted approach to overcoming antibiotic resistance","volume":"197","author":"Olawade DB","year":"2024","unstructured":"Olawade DB, Fapohunda O, Egbon E, Ebiesuwa OA, Usman SO, Faronbi AO, Fidelis SC. Phage therapy: a targeted approach to overcoming antibiotic resistance. Microb Pathog. 2024, 197:107088. 10.1016\/j.micpath.2024.107088","journal-title":"Microb Pathog"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01889","article-title":"Emerging trends in \u201csmart probiotics\u201d: functional consideration for the development of novel health and industrial applications","volume":"8","author":"El Hage R","year":"2017","unstructured":"El Hage R, Hernandez-Sanabria E, Van de Wiele T. Emerging trends in \u201csmart probiotics\u201d: functional consideration for the development of novel health and industrial applications. Front Microbiol. 2017, 8:1889. 10.3389\/fmicb.2017.01889","journal-title":"Front Microbiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081871","article-title":"The role of fecal microbiota transplantation (FMT) in the management of metabolic diseases in humans: a narrative review","volume":"12","author":"Zikou E","year":"2024","unstructured":"Zikou E, Koliaki C, Makrilakis K. The role of fecal microbiota transplantation (FMT) in the management of metabolic diseases in humans: a narrative review. Biomedicines. 2024, 12:1871. 10.3390\/biomedicines12081871","journal-title":"Biomedicines"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-024-05230-5","article-title":"Fecal microbiota transplantation validates the importance of gut microbiota in an ApoE(-\/-) mouse model of chronic apical periodontitis-induced atherosclerosis","volume":"24","author":"Gan G","year":"2024","unstructured":"Gan G, Zhang R, Zeng Y, et al.. Fecal microbiota transplantation validates the importance of gut microbiota in an ApoE(-\/-) mouse model of chronic apical periodontitis-induced atherosclerosis. BMC Oral Health. 2024, 24:1455. 10.1186\/s12903-024-05230-5","journal-title":"BMC Oral Health"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00728-w","article-title":"Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q\/TNF-related protein 9 genetic deficiency","volume":"54","author":"Kim ES","year":"2022","unstructured":"Kim ES, Yoon BH, Lee SM, et al.. Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q\/TNF-related protein 9 genetic deficiency. Exp Mol Med. 2022, 54:103-14. 10.1038\/s12276-022-00728-w","journal-title":"Exp Mol Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.420","article-title":"Probiotics, prebiotics, and postbiotics in health and disease","volume":"4","author":"Ji J","year":"2023","unstructured":"Ji J, Jin W, Liu SJ, Jiao Z, Li X. Probiotics, prebiotics, and postbiotics in health and disease. MedComm (2020). 2023, 4:e420. 10.1002\/mco2.420","journal-title":"MedComm (2020)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/nu14010137","article-title":"Polyphenols - gut microbiota interrelationship: a transition to a new generation of prebiotics","volume":"14","author":"Plamada D","year":"2021","unstructured":"Plamada D, Vodnar DC. Polyphenols - gut microbiota interrelationship: a transition to a new generation of prebiotics. Nutrients. 2021, 14:137. 10.3390\/nu14010137","journal-title":"Nutrients"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103511","article-title":"Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: results from the randomized GutHeart trial","volume":"70","author":"Awoyemi A","year":"2021","unstructured":"Awoyemi A, Mayerhofer C, Felix AS, et al.. Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: results from the randomized GutHeart trial. EBioMedicine. 2021, 70:103511. 10.1016\/j.ebiom.2021.103511","journal-title":"EBioMedicine"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3900835","article-title":"Probiotics bring new hope for atherosclerosis prevention and treatment","volume":"2022","author":"Zhai T","year":"2022","unstructured":"Zhai T, Wang P, Hu X, Zheng L. Probiotics bring new hope for atherosclerosis prevention and treatment. Oxid Med Cell Longev. 2022, 2022:3900835. 10.1155\/2022\/3900835","journal-title":"Oxid Med Cell Longev"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12112246","article-title":"The bidirectional relationship between cardiovascular medications and oral and gut microbiome health: a comprehensive review","volume":"12","author":"Dharmarathne G","year":"2024","unstructured":"Dharmarathne G, Kazi S, King S, Jayasinghe TN. The bidirectional relationship between cardiovascular medications and oral and gut microbiome health: a comprehensive review. Microorganisms. 2024, 12:2246. 10.3390\/microorganisms12112246","journal-title":"Microorganisms"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359240-molecular-mechanisms-and-emerging-precision-therapeutics-in-the-gut-microbiota-cardiovascular-axis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T08:02:32Z","timestamp":1745654552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359240-molecular-mechanisms-and-emerging-precision-therapeutics-in-the-gut-microbiota-cardiovascular-axis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.83022","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,26]]}}}